Alagille Syndrome
23
5
5
15
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 23 trials
100.0%
+13.5% vs benchmark
17%
4 trials in Phase 3/4
40%
6 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (23)
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease